Targets › F2R
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Mar 2027.
High affinity receptor that binds the activated thrombin, leading to calcium release from intracellular stores. The thrombin-activated receptor signaling pathway is mediated through PTX-insensitive G proteins, activation of phospholipase C resulting in the production of 1D-myo-inositol 1,4,5-trisphosphate (InsP3) which binds to InsP3 receptors causing calcium release from the stores (By similarity). (UniProt, P25116)
Open in Phaseline: the race on F2R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhujiang Hospital | Nafamostat Mesilate Serine protease inhibitor; anticoagulant | F2, F2R, PLAU | Phase 2 | Continuous Renal Replacement Therapy (CRRT) | Mar 2027 |
Continuous Renal Replacement Therapy (CRRT) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.